A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary) ; Adebrelimab; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 29 Jan 2025 New trial record